Factor Xa inhibitors: all 607 studies that test it
Page 5 of 7. Open to participants first (111), then studies with results posted, then the rest; newest registration first within each.
- Rivaroxaban as Thrombosis Prophylaxis in Bariatric SurgeryCompletedNCT03522259Phase 2
- Lixiana Acute Stroke Evaluation RegistryCompletedNCT03494530Phase 4
- Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF)Status unknownNCT03490994Phase 4
- A Pilot Study on Edoxaban for the Resolution of Left Atrial Thrombosis in Patients With Non-valvular Atrial FibrillationCompletedNCT03489395Phase 2
- Apixaban in End-stage Kidney Disease : A Pharmacokinetics StudyCompletedNCT03456648Phase 2
- Early Administration of Edoxaban After Acute Ischemic Stroke in Patients With Non-valvular Atrial FibrillationCompletedNCT03433235Phase 2
- Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple MyelomaActive, not recruitingNCT03428373Phase 2/3
- The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa AntagonistCompletedNCT03397888Phase 1
- Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary SyndromeCompletedNCT03363035Phase 4
- The Safety and Efficacy Of Rivaroxaban and Ticagrelor for Patients With Atrial Fibrillation After Percutaneous Coronary InterventionCompletedNCT03331484Phase 3
- Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer PatientsCompletedNCT03282643Phase 1/2
- Study of Prophylactic Effect of Rivaroxaban on Venous Thromboembolism in AECOPDStatus unknownNCT03277001Not applicable
- Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage ClosureCompletedNCT03273322Phase 2/3
- Explore the Efficacy and Safety of edoxabaN in Patients After Heart Valve Repair or Bioprosthetic vaLve Replacement (ENAVLE Trial)CompletedNCT03244319Phase 3
- Efficacy and Safety of Rivaroxaban in Acute Non-neoplastic Portal Vein Thrombosis in HCVCompletedNCT03201367Not applicable
- Apixaban For Thromboprophylaxis In Patients With Acute Spinal Cord InjuryTerminatedNCT03200613Phase 2
- Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated CirrhosisStatus unknownNCT03193502Phase 3
- Comparison of the Efficacy of Rivroxaban to Coumadin( Warfarin ) in Cerebral Venous ThrombosisStatus unknownNCT03191305Not applicable
- Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral AnticoagulantsCompletedNCT03181386Phase 3
- Study of Rivaroxaban for CeREbral Venous ThrombosisCompletedNCT03178864Phase 2
- Start or STop Anticoagulants Randomised Trial (SoSTART)CompletedNCT03153150Phase 3
- Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded TrialCompletedNCT03148457Not applicable
- A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous ThromboembolismStatus unknownNCT03139487Phase 2
- Evolution of Coagulation Activity in Non Valvular Atrial Fibrillation Patients Under ApixabanTerminatedNCT03136510Not applicable
- The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)Active, not recruitingNCT03129555Phase 4
- The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial FibrillationActive, not recruitingNCT03129490Phase 4
- A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage ClosureStatus unknownNCT03088072Phase 4
- Drug Interaction Study of Apixaban With Cyclosporine and TacrolimusCompletedNCT03083782Phase 1
- A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet AlfaCompletedNCT03083704Phase 1
- Bioequivalence Study of Rivaroxaban From Repatoxaban 10 mg Tablets (Horus for Pharmaceutical Industries, Egypt) and Xarelto® 10 mg Tablets (Janssen Pharm., Licensed From: Bayer Healthcare, Germany)CompletedNCT03071380Phase 1
- Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer.CompletedNCT03055026Phase 3
- Anticoagulation for Advanced Cirrhotic Patients After TIPSStatus unknownNCT03005444Not applicable
- Rivaroxaban or Aspirin for Biological Aortic ProsthesisStatus unknownNCT02974920Phase 4
- Absorption of Rivaroxaban in Patients With Cervical Spinal Cord InjuryWithdrawnNCT02970773Phase 4
- Comparison of Two Doses of Edoxaban Using Different Tests (Assays) and Clinical OutcomesCompletedNCT02964949Not applicable
- Sidlenafil in Combination With Oral Anticoagulants in Patients With Intermediate-high Risk of Pulmonary EmbolismStatus unknownNCT02946944Phase 1
- Apixaban for Routine Management of Upper Extremity Deep Venous ThrombosisTerminatedNCT02945280Phase 4
- ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON)CompletedNCT02935855Phase 4
- Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)CompletedNCT02933697Phase 3
- Rivaroxaban for Patients With Antiphospholipid SyndromeCompletedNCT02926170Phase 3
- Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy ParticipantsCompletedNCT02912234Phase 1
- PK of Rivaroxaban in Bariatric Patients - ExtensionCompletedNCT02832947Phase 1
- INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-InferiorityCompletedNCT02832544Phase 3
- INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, SuperiorityWithdrawnNCT02832531Phase 3
- Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee ReplacementCompletedNCT02810704Phase 4
- Cancer Associated Thrombosis, a Pilot Treatment Study Using RivaroxabanCompletedNCT02746185Phase 3
- COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome TrialsWithdrawnNCT02723981Phase 4
- Comparison Between Xarelto Versus Warfarin in the Recanalization Rate of Deep Venous Thrombosis in Patients Legs.Status unknownNCT02704598Not applicable
- Apixaban in HemodialysisCompletedNCT02672709Phase 4
- Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial FibrillationStatus unknownNCT02666157Phase 4
- Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic StenosisCompletedNCT02664649Phase 3
- Venous Thromboembolism in Renally Impaired Patients and Direct Oral AnticoagulantsTerminatedNCT02664155Phase 3
- Effect of Activated Charcoal on Rivaroxaban Pharmacokinetics in Healthy SubjectsCompletedNCT02657512Phase 1
- Multicenter Prospective Randomized Trial of the Effect of Rivaroxaban on Survival and Development of Complications of Portal Hypertension in Patients With CirrhosisStatus unknownNCT02643212Phase 3
- Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease StudyStatus unknownNCT02642419Phase 4
- Treatment of Splanchnic Vein Thrombosis With Rivaroxaban. A Pilot, Prospective Cohort StudyStatus unknownNCT02627053Phase 3
- Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2 in Hemodialysis PatientsCompletedNCT02610933Phase 4
- Pharmacokinetics of Apixaban in Nephrotic SyndromeCompletedNCT02599532Phase 1
- A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban FormulationsCompletedNCT02596100Phase 1
- Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer PatientsTerminatedNCT02583191Phase 3
- Apixaban as Treatment of Venous Thrombosis in Patients With Cancer: The CAP StudyCompletedNCT02581176Phase 4
- Edoxaban in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and ClopidogrelCompletedNCT02567461Phase 4
- Apixaban After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial FibrillationCompletedNCT02565693Phase 2
- A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy ParticipantsCompletedNCT02561923Phase 1
- Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.CompletedNCT02555111Phase 3
- Pleotropic Effect of New Oral AnticoagulantsStatus unknownNCT02544932Phase 3
- Bioequivalence Study of RivaroxabanCompletedNCT02537457Phase 1
- Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male SubjectsCompletedNCT02537405Phase 1
- Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in ChildrenCompletedNCT02497716Phase 1
- Rivaroxaban for Scheduled Work-up of DVT - The Ri-Schedule StudyCompletedNCT02486445Phase 3
- Apixaban in Patients Who Undergo CIED Procedure- Randomized Pilot StudyWithdrawnNCT02450682Phase 2
- Rivaroxaban in Bariatric SurgeryCompletedNCT02438098Phase 1
- Apixaban for Treatment of Embolic Stroke of Undetermined SourceCompletedNCT02427126Phase 3
- PROphylaxis in NOn Major Orthopaedic SurgeryTerminatedNCT02401594Phase 3
- Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AFTerminatedNCT02387229Phase 3
- Prophylaxis of Deep Vein Thrombosis Following Total Hip ArthroplastyCompletedNCT02379663Phase 4
- Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical EmboliWithdrawnNCT02378623Phase 2
- Relative Bioavailability Study in Healthy Subjects Comparing 2 Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting ConditionsCompletedNCT02367027Phase 1
- Anti-inflammatory Effects of Rivaroxaban Versus DabigatranStatus unknownNCT02331602Phase 4
- RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER TrialCompletedNCT02303795Phase 2
- Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid SyndromeCompletedNCT02295475Phase 4
- A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance HemodialysisCompletedNCT02289703Phase 1
- Comparative Study of Prophylactic Agent for Venous Thromboembolism After Total Knee ArthroplastyCompletedNCT02271399Phase 2
- Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy SubjectsCompletedNCT02262533Phase 1
- Phase 1 Drug Interaction Study of the Effect of Apixaban on the PK of Digoxin in Healthy SubjectsCompletedNCT02262520Phase 1
- Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist TherapyCompletedNCT02227550Phase 4
- Edoxaban for TIA and Acute Minor StrokeStatus unknownNCT02221102Phase 2/3
- Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation TrialCompletedNCT02168829Phase 4
- Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulationCompletedNCT02161965Phase 4
- Rivaroxaban in Thrombotic Antiphospholipid SyndromeTerminatedNCT02157272Phase 3
- Comparison of Antithrombotic Treatments After Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve.TerminatedNCT02128841Phase 2
- Rivaroxaban Anticoagulation for Superficial Vein ThrombosisCompletedNCT02123524Phase 3
- Rivaroxaban for Antiphospholipid Antibody SyndromeCompletedNCT02116036Phase 4
- Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.Status unknownNCT02085824Not applicable
- Triple vs. Dual TherapyCompletedNCT02080858Phase 1
- Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDsCompletedNCT02066454Phase 3
- Rivaroxaban Effects in Subjects Who Have Undergone Gastric Bypass SurgeryTerminatedNCT02058199Phase 1
- Evaluation of Wound Drainage After Knee or Hip ArthroplastyWithdrawnNCT02054936Phase 4
- Apixaban for the Prevention of Venous Thromboembolism in Cancer PatientsCompletedNCT02048865Phase 2
- A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on AnticoagulationCompletedNCT02047565Phase 1